World's Best Scientists 2026 revealed!
VIEW LIST
Carlos H. Barrios

D-Index & Metrics

Medicine

D-Index
75
Citations
54121
World Ranking
18949
National Ranking
55

Carlos H. Barrios publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Carlos H. Barrios sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 215 publications — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Carlos H. Barrios D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Carlos H. Barrios sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 75 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Carlos H. Barrios is affiliated with the Pontifical Catholic University of Rio Grande do Sul in Brazil. Their research primarily focuses on oncology and related medical fields, with a significant number of publications contributing to cancer research and treatment.

The main fields of study covered in their work include Medicine and Biochemistry, Genetics and Molecular Biology. Within these disciplines, the subfields of Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Economics and Econometrics, and Genetics are notable areas of contribution.

The primary topics addressed in their research encompass:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Economic and Financial Impacts of Cancer

Carlos H. Barrios has published extensively in various scientific venues, with frequent contributions to:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Clinical Cancer Research
  • ESMO Open

Frequent coauthors collaborating with Barrios include Sherene Loi, Hope S. Rugo, Nadia Harbeck, Javier Cortés, and Seock-Ah Im.

Significant recent papers include:

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial (2020, The Lancet)
  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma (2021, New England Journal of Medicine)
  • Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC (2020, New England Journal of Medicine)
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer (2021, Annals of Oncology)
  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial (2020, The Lancet)

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  • Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

    Cora N. Sternberg;Ian D. Davis;Jozef Mardiak;Cezary Szczylik

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

    Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

    Javier Cortes;David W Cescon;Hope S Rugo;Zbigniew Nowecki

  • Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    Roy S Herbst;Giuseppe Giaccone;Filippo de Marinis;Niels Reinmuth

  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Peter Schmid;Hope S Rugo;Sylvia Adams;Andreas Schneeweiss

  • Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

    Ernst-Ruediger Kuse;Ploenchan Chetchotisakd;Clovis Arns da Cunha;Markus Ruhnke

  • Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

    F. Saad;J. E. Brown;C. Van Poznak;T. Ibrahim

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

    Elizabeth A Mittendorf;Hong Zhang;Carlos H Barrios;Shigehira Saji

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

    F. Cardoso;A. Costa;L. Norton;E. Senkus

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

    Pasi A Jänne;Alice T Shaw;José Rodrigues Pereira;Gaëlle Jeannin

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Planning cancer control in Latin America and the Caribbean

    Paul E. Goss;Brittany L. Lee;Brittany L. Lee;Tanja Badovinac-Crnjevic;Kathrin Strasser-Weippl

  • Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Arlene Chan;Suzette Delaloge;Frankie A Holmes;Beverly Moy

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

    Evandro De Azambuja;Andrew P. Holmes;Martine Piccart-Gebhart;Eileen Holmes

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Hiroji Iwata
Hiroji Iwata Aichi Cancer Center
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Véronique Diéras
Véronique Diéras Institute Curie
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Miguel Martin
Miguel Martin Complutense University of Madrid
Sylvia Adams
Sylvia Adams New York University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Suzette Delaloge
Suzette Delaloge Institut Gustave Roussy
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open doors to rewarding healthcare careers, even if studying Medicine in the USA isn’t your chosen path. Many students pursue nursing programs for their flexibility, affordability, and strong job prospects.

For aspiring nurses, there are several routes available. If you are looking for cost-effective advanced degrees, the cheapest phd nursing programs offer opportunities to specialize further while minimizing student debt. Registered Nurses (RNs) interested in advancing may consider affordable rn to bsn programs, which are designed for working professionals who want to earn their bachelor’s remotely.

Non-nursing majors have quick entry options into the field through accredited online direct entry msn programs for non-nursing majors. These programs allow individuals from other backgrounds to transition into nursing leadership and advanced clinical roles.

If you are searching for accessible routes, the easiest bsn program to get into can simplify the admission process and help you quickly start your healthcare career, all from the flexibility of home.

Best Scientists Citing Carlos H. Barrios

Toni K. Choueiri

Toni K. Choueiri

Harvard University

Publications: 149

Brian I. Rini

Brian I. Rini

Vanderbilt University Medical Center

Publications: 118

Robert J. Motzer

Robert J. Motzer

Memorial Sloan Kettering Cancer Center

Publications: 114

Bernard Escudier

Bernard Escudier

Institut Gustave Roussy

Publications: 114

Camillo Porta

Camillo Porta

University of Bari Aldo Moro

Publications: 110

Evandro de Azambuja

Evandro de Azambuja

Université Libre de Bruxelles

Publications: 110

Giuseppe Curigliano

Giuseppe Curigliano

University of Milan

Publications: 93

Thomas Powles

Thomas Powles

Queen Mary University of London

Publications: 89

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 81

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 80

Javier Cortes

Javier Cortes

Vall d'Hebron Hospital Universitari

Publications: 78

Laurence Albiges

Laurence Albiges

Institut Gustave Roussy

Publications: 77

Hope S. Rugo

Hope S. Rugo

University of California, San Francisco

Publications: 72

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 68

José Baselga

José Baselga

Memorial Sloan Kettering Cancer Center

Publications: 67

Seock-Ah Im

Seock-Ah Im

Seoul National University Hospital

Publications: 65

Trending Scientists

Phillip L. Geissler

Phillip L. Geissler

University of California, Berkeley

Kinji Ohno

Kinji Ohno

Nagoya University

Julia L. Evans

Julia L. Evans

The University of Texas at Dallas

Eero Pekkonen

Eero Pekkonen

University of Helsinki

Takashi Hanakawa

Takashi Hanakawa

Kyoto University

Dean G. Tang

Dean G. Tang

Roswell Park Cancer Institute

Karel Breiter

Karel Breiter

Czech Academy of Sciences

Kotagiri Ramamohanarao

Kotagiri Ramamohanarao

University of Melbourne

Ilya Sutskever

Ilya Sutskever

OpenAI

Norm Archer

Norm Archer

McMaster University

Yingjiu Li

Yingjiu Li

University of Oregon

Karin Bäckstrand

Karin Bäckstrand

Stockholm University

Ronald M. Lechan

Ronald M. Lechan

Tufts Medical Center

Steven J. Linton

Steven J. Linton

Örebro University

David H. Wahl

David H. Wahl

University of Illinois at Urbana-Champaign

Thomas Hovestadt

Thomas Hovestadt

University of Würzburg

Related Medicine Rankings & Guides

August 2026 Best Nursing Certifications to Consider

August 2026 Best Nursing Certifications to Consider
2026 Best Online Nursing Programs in Iowa – Accredited RN to BSN Programs

2026 Best Online Nursing Programs in Iowa – Accredited RN to BSN Programs
2026 Most Affordable Online BSN to DNP Degree Programs

2026 Most Affordable Online BSN to DNP Degree Programs
2026 Best Nursing Schools in Texas – Accredited ADN, BSN, MSN Programs

2026 Best Nursing Schools in Texas – Accredited ADN, BSN, MSN Programs
2026 Most Affordable Online LPN to RN Degree Programs

2026 Most Affordable Online LPN to RN Degree Programs
2026 Fastest Online MSN in Psychiatric Mental Health NP Programs

2026 Fastest Online MSN in Psychiatric Mental Health NP Programs
2026 Best Shortest Online DNP Programs

2026 Best Shortest Online DNP Programs
2026 Best Online Associate in Sonography Programs

2026 Best Online Associate in Sonography Programs
2026 Best Online BSN to FNP Programs

2026 Best Online BSN to FNP Programs
2026 Best Online Nursing Degree Programs

2026 Best Online Nursing Degree Programs
2026 Best Nurse Practitioner Programs in Connecticut – Accredited Schools Online & Campus

2026 Best Nurse Practitioner Programs in Connecticut – Accredited Schools Online & Campus
2026 Fastest Online Graduate Certificate Nurse Midwifery Programs

2026 Fastest Online Graduate Certificate Nurse Midwifery Programs
2026 Fastest Online Medical Assistant Associate Degree Programs

2026 Fastest Online Medical Assistant Associate Degree Programs
2026 Easiest RN-to-MSN Online Programs to Get Into

2026 Easiest RN-to-MSN Online Programs to Get Into
2026 Most Affordable Online MSN in Nurse Executive Leadership Programs

2026 Most Affordable Online MSN in Nurse Executive Leadership Programs
2026 Best Online Pharmacy Technician Associate Programs

2026 Best Online Pharmacy Technician Associate Programs
2026 Fastest Online Adult-Gerontology PCNP Graduate Certificate Programs

2026 Fastest Online Adult-Gerontology PCNP Graduate Certificate Programs
2026 Most Affordable Online Accelerated BSN Programs for Non-Nurses

2026 Most Affordable Online Accelerated BSN Programs for Non-Nurses
2026 Best Online Nursing Programs in Washington: Accredited RN to BSN Programs

2026 Best Online Nursing Programs in Washington: Accredited RN to BSN Programs
2026 Best Online Nursing Programs in Maine – Accredited RN to BSN Programs

2026 Best Online Nursing Programs in Maine – Accredited RN to BSN Programs
2026 Easiest Accelerated BSN Programs to Get Into

2026 Easiest Accelerated BSN Programs to Get Into

Recently Published Articles

2026 Different Types of Healthcare Administration Degrees and Their Salaries

2026 Different Types of Healthcare Administration Degrees and Their Salaries
2026 Online Finance Degree Master's Programs with No GRE or GMAT Requirements

2026 Online Finance Degree Master's Programs with No GRE or GMAT Requirements
2026 Online Criminal Justice Degree Programs Costs: Tuition & Fees

2026 Online Criminal Justice Degree Programs Costs: Tuition & Fees
2026 Cheapest Accredited Online Chemistry Degree Programs: Tuition, Fees, and Financial Aid

2026 Cheapest Accredited Online Chemistry Degree Programs: Tuition, Fees, and Financial Aid
2026 Biology Degree Master's Programs You Can Get Into Right Now (Eligibility-Based Matches)

2026 Biology Degree Master's Programs You Can Get Into Right Now (Eligibility-Based Matches)
August 2026 Most Affordable Online PhD in Nursing (DNP) Programs

August 2026 Most Affordable Online PhD in Nursing (DNP) Programs
2026 How Fast Can You Get a Mechanical Engineering Degree Online?

2026 How Fast Can You Get a Mechanical Engineering Degree Online?
2026 Can You Get a Data Science Degree Master's Without a Related Bachelor's Degree?

2026 Can You Get a Data Science Degree Master's Without a Related Bachelor's Degree?
2026 ESL Teacher Requirements & ESOL Certification in Massachusetts

2026 ESL Teacher Requirements & ESOL Certification in Massachusetts
2026 Sports Analytics Internship Requirements: Hours, Placements, and Supervision

2026 Sports Analytics Internship Requirements: Hours, Placements, and Supervision
2026 Online Human Services Degrees With Family and Child Services Concentrations

2026 Online Human Services Degrees With Family and Child Services Concentrations
2026 Best Online Public Health Degree Master's Programs for Working Professionals

2026 Best Online Public Health Degree Master's Programs for Working Professionals
2026 Best Accelerated RN to BSN to MSN Online Bridge Programs

2026 Best Accelerated RN to BSN to MSN Online Bridge Programs
2026 Easiest Online Construction Management Master's Degree Programs That Pay Well: High-Salary Degrees with Simple Admissions

2026 Easiest Online Construction Management Master's Degree Programs That Pay Well: High-Salary Degrees with Simple Admissions
2026 What Prerequisites Do You Need for an Engineering Management Master's Degree? Entry Requirements, Credits & Eligibility Rules

2026 What Prerequisites Do You Need for an Engineering Management Master's Degree? Entry Requirements, Credits & Eligibility Rules
2026 Which Medical Billing & Coding Specializations Have the Best Job Outlook?

2026 Which Medical Billing & Coding Specializations Have the Best Job Outlook?
2026 Easiest Online Industrial Organizational Psychology Master's Degree Programs That Pay Well: High-Salary Degrees with Simple Admissions

2026 Easiest Online Industrial Organizational Psychology Master's Degree Programs That Pay Well: High-Salary Degrees with Simple Admissions
2026 Shortest Online Homeland Security Degree Master's Programs That Pay Well: Cost, Time to Completion, and Salary Outlook

2026 Shortest Online Homeland Security Degree Master's Programs That Pay Well: Cost, Time to Completion, and Salary Outlook
2026 Best Accredited Online Addiction Psychology Bachelor's Degree Programs

2026 Best Accredited Online Addiction Psychology Bachelor's Degree Programs
2026 Most Affordable Online Animation Degree Programs

2026 Most Affordable Online Animation Degree Programs
2026 Online Nutrition Degree Programs for Veterans: GI Bill Benefits, Costs & Top Considerations

2026 Online Nutrition Degree Programs for Veterans: GI Bill Benefits, Costs & Top Considerations